These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28533094)

  • 1. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?
    Kunkel A; Furin J; Cohen T
    Lancet Infect Dis; 2017 Dec; 17(12):e429-e433. PubMed ID: 28533094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
    Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
    Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
    Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
    Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K
    Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Vasilyeva I; Mariandyshev A; Kazennyy B; Davidavičienė E; Lounis N; Keim S;
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31097518
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First use of bedaquiline in a patient with XDR-TB in Singapore.
    Chua AP; Hoo GS; Chee CB; Wang YT
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26400590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
    Shah I; Gandhi S; Shetty NS
    Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis.
    Martín-García M; Esteban J
    Expert Opin Pharmacother; 2021 Apr; 22(5):535-541. PubMed ID: 33393406
    [No Abstract]   [Full Text] [Related]  

  • 16. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 18. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected questions and controversies about bedaquiline: a view from the field.
    Dheda K; Esmail A; Limberis J; Maartens G
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):24-32. PubMed ID: 28240569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.